Paul G. Allen Frontiers Group [to 31 Oct 2020]
No new digest content identified.


BARDA – U.S. Department of HHS [to 31 Oct 2020]
October 28, 2020: HHS, DOD Collaborate on Plans to Purchase of Lilly Investigational Therapeutic to Treat COVID-19
…the U.S. Department of Health and Human Services (HHS) and Department of Defense (DoD) today announced an agreement with Eli Lilly and Company to purchase the first doses of the company’s COVID-19 investigational antibody therapeutic bamlanivimab, also known as LY-CoV555. These doses will be available for patient care if the U.S. Food and Drug Administration (FDA) authorizes use of the therapeutic, as outlined in agency guidance


BMGF – Gates Foundation [to 31 Oct 2020]
Press Releases and Statements
No new digest content identified.


Bill & Melinda Gates Medical Research Institute [to 31 Oct 2020]
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.


CARB-X [to 31 Oct 2020]
No new digest content identified.


CEPI – Coalition for Epidemic Preparedness Innovations [to 31 Oct 2020]
Latest News
COVAX welcomes appointment of civil society representatives
Those selected will provide valuable technical expertise and use their experiences in a number of key COVAX groups working to ensure equitable access to COVID-19 vaccines.
30 Oct 2020
[See Milestones above for detail]

Italy pledges first EUR 5 million funding to CEPI to advance COVID-19 vaccine development efforts
Financial contribution is part of a larger donation to support CEPI’s work.
28 Oct 2020


EDCTP [to 31 Oct 2020]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.


Emory Vaccine Center [to 31 Oct 2020]
Vaccine Center News
No new digest content identified.


European Medicines Agency [to 31 Oct 2020]
News & Press Releases
Extra transparency measures for COVID-19 vaccines and therapeutics
News 30/10/2020
Today the European Medicines Agency (EMA) has implemented two further extra transparency measures for COVID-19 medicines, by publishing both the clinical data in support of the authorisation of Veklury (remdesivir) and information on the COVID-19 treatments and vaccines that have received scientific advice or informal guidance from EMA’s pandemic Task Force (COVID-ETF).
These are the latest measures in EMA’s drive to maximise the transparency of its regulatory activities on treatments and vaccines for COVID-19…

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 26-29 October 2020
News 30/10/2020
PRAC reviews EMA guidance on risk management plan requirements for COVID-19 vaccines
EMA’s safety committee (PRAC) has reviewed the guidance developed by EMA for pharmaceutical companies on how to prepare risk management plans (RMPs) for COVID-19 vaccines.
As for any medicine, companies are required to submit an RMP for COVID-19 vaccines when they apply for a marketing authorisation. Such a plan explains how the company that markets the vaccine must monitor and report on its safety, and what measures they must put in place to manage any risks. Importantly, RMPs are continually updated throughout the lifetime of the vaccine as new information becomes available.
The guidance is for COVID-19 vaccines only and complements the already existing guidelines on the RMP format in the EU, which apply to all medicines.
The guidance will now be sent for adoption to EMA’s human medicines committee (CHMP) and will be made public once it is adopted by the CHMP


European Vaccine Initiative [to 31 Oct 2020]
Latest News
No new digest content identified.


FDA [to 31 Oct 2020]
Press Announcements /Selected Details
October 30, 2020 – Coronavirus (COVID-19) Update: October 30, 2020

October 30, 2020 – FDA Publishes List of Essential Medicines, Medical Countermeasures, Critical Inputs Required by Executive Order
As the U.S. Food and Drug Administration continues our work to address the current pandemic, we are also looking ahead to prepare for the next potential public health emergency. A recent executive order directed the agency, in consultation with federal partners, to identify a list of essential medicines, medical countermeasures and critical inputs that are medically necessary to have available at all times in an amount adequate to serve patient needs and in the appropriate dosage forms.
The goal of this work is to ensure the American public is protected against outbreaks of emerging infectious diseases, such as COVID-19, as well as chemical, biological, radiological and nuclear threats. To accomplish this goal, the executive order seeks to ensure sufficient and reliable, long-term domestic production of these products, and to minimize potential shortages by reducing our dependence on foreign manufacturers of these products…

October 28, 2020 – Coronavirus (COVID-19) Update: October 28, 2020

October 26, 2020 – Coronavirus (COVID-19) Update: Daily Roundup October 26, 2020


FDA – COVID-19 Vaccines [to 31 Oct 2020]
Upcoming Events
I’m the FDA point person on COVID-19 vaccines. We’ll make sure they’re safe and effective.
FDA Center for Biologics Evaluation and Research Director Dr. Peter Marks

FDA Commissioner Stephen Hahn on the Radio: COVID-19 & FDA
FDA Commissioner Stephen Hahn joins a radio morning show to discuss the FDA’s role in the fight against COVID-19.


Fondation Merieux [to 31 Oct 2020]
News, Events
The REDISSE project in West Africa, for the improvement of disease surveillance in ECOWAS countries continues with a second phase
October 29, 2020, Benin, Niger, Nigeria, Mali and Mauritania
The Mérieux Foundation starts the second phase of its mandate as part of the REDISSE project aiming at strengthening disease …

HINTT project team publishes results of its multicentered cohort study on tuberculosis
October 26, 2020, Lyon (France)
High white blood cell counts and low lymphocyte proportions before treatment are significantly associated with the risk of tuberculosis treatment …


Gavi [to 31 Oct 2020]
News releases
30 October 2020
COVAX welcomes appointment of civil society representatives
[See Milestones above for detail]

28 October 2020
Gavi signs statement of intent to procure 200 million doses of Sanofi-GSK COVID-19 vaccine candidate for the COVAX Facility
Geneva, 28 October 2020 – Gavi, the Vaccine Alliance announced today that it had signed a Statement of Intent with Sanofi and GSK to provide 200 million doses of the companies’ adjuvanted recombinant protein COVID-19 vaccine to the COVAX Facility. The non-binding statement is a critical step toward making sure doses of the vaccine, if approved and licensed, will be made available to all countries and economies participating in the COVAX Facility.
“The signing of this statement of intent is an important step forward in our partnership, and I welcome Sanofi and GSK’s commitment to the COVAX goal of equitable access to COVID-19 vaccines,” said Seth Berkley, CEO of Gavi. “Gavi is seeking to secure doses of the most promising vaccine candidates – so that the 184 participants involved in the COVAX Facility can make sure their most at-risk groups, such as healthcare workers, have rapid access to doses of a safe and effective vaccine. That is the world’s best chance to end the acute stage of this pandemic, and we encourage other vaccine manufacturers to work with us towards that shared global goal.”…

27 October 2020
Myanmar introduces cervical cancer vaccine nationally, despite COVID-19 challenges
:: Around 450,000 girls aged 9-101 will receive the human papillomavirus (HPV) vaccine, which protects against the leading cause of cervical cancer
:: Myanmar currently has the second-highest incidence of cervical cancer in Southeast Asia
:: The vaccine will be rolled out with stringent COVID-19 safety measures in place, including physical distancing and catch-up immunisations for the 73 “stay-at-home townships” currently under tighter restrictions


GHIT Fund [to 31 Oct 2020]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that No new digest content identified.


Global Fund [to 31 Oct 2020]
Strategy Development Open Consultation: First Round of Input
30 October 2020
Approximately 250 individuals and groups have contributed to the first round of input into the Open Consultation on the development of the next Global Fund Strategy, a multiyear road map for our partnership’s future. Input is synthesized in a new presentation:
Strategy Development Open Consultation Synthesis of First Round of Input
download in Français | English
This synthesis covers the responses contributed as of 1 September 2020, which comes from civil society, communities, technical experts, County Coordinating Mechanisms, multilateral partners, bilateral partners, implementers and a range of other stakeholders across regions globally…


Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 31 Oct 2020]
No new digest content identified.


Hilleman Laboratories [to 31 Oct 2020]
No new digest content identified.


Human Vaccines Project [to 31 Oct 2020]
Press Releases
No new digest content identified.


IAVI [to 31 Oct 2020]
October 27, 2020
Support from the U.S. Department of Defense Will Accelerate Progress on Vaccine Candidate for COVID-19, IAVI Says
NEW YORK — OCTOBER 27, 2020 — IAVI announced today the award of US$26.7M from the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DoD) to support IAVI’s recombinant vesicular stomatitis virus (rVSV) vectored SARS-CoV-2 vaccine candidate. DTRA’s commitment will enable critical nonclinical development on the vaccine candidate that IAVI is developing in partnership with Merck (known as MSD outside the United States and Canada).
DTRA’s award will facilitate the vaccine candidate’s clinical development path to licensure by supporting work at IAVI’s Vaccine Design and Development Laboratory (DDL) in Brooklyn, New York, to characterize immune responses in animals and demonstrate the safety and efficacy profile of rVSVΔG-SARS-CoV-2 vaccination in animals. These nonclinical data will be essential to supplement the clinical data package and to inform the most effective use of the vaccine in an ongoing pandemic. The award from DTRA comes from its Science and Technology New Initiatives, under the topic area Chemical/Biological…



International Coalition of Medicines Regulatory Authorities [ICMRA]
Selected Statements, Press Releases, Research
No new digest content identified.



International Generic and Biosimilar Medicines Association [IGBA]
No new digest content identified.



IFFIm Appoints Kenneth Lay as Chair of its Board of Directors
29 Oct 2020
Lay succeeds Cyrus Ardalan, who introduced CEPI programme and led successful replenishment raising over US$ 926 million London, 29 October 2020 – The Board of Directors of the International Finance Facility for Immunisation (IFFIm) has selected Kenneth Lay, a former World Bank executive with extensive capital markets experience, as its next Chair….

IFFIm Prices US$500 Million 3-year Benchmark Vaccine Bonds
29 Oct 2020
IFFIm today priced US$ 500 million, 3-year fixed rate benchmark Vaccine Bonds that will provide Gavi, the Vaccine Alliance, flexible funding for its core immunisation programmes and efforts to develop and distribute eventual COVID-19 vaccines to countries around the world, particularly the poorest.
[See Milestones above for detail]


IFRC [to 31 Oct 2020]
Selected Press Releases, Announcements
Azerbaijan Red Crescent Society and IFRC mourn death of volunteer
The Azerbaijan Red Crescent Society and IFRC have today condemned the death of a Red Crescent volunteer who was providing humanitarian assistance in the town of Barda, Azerbaijan.
29 October 2020

Major typhoon devastates areas of central Viet Nam
Kuala Lumpur/Hanoi/Geneva, 29 October 2020 – A major typhoon has devastated areas of central Vietnam, with dozens of people feared dead in tragic landslides in Quang Nam.  There are 53 people buried and feared dead in two landslides caused by the storm …
29 October 2020

Homes of 1 million people in ruin as major typhoon hits Viet Nam
Kuala Lumpur/Hanoi/Geneva, 28 October, 2020 – Catastrophic floods across central Vietnam have already ruined the homes of more than one million people as yet another major storm takes aim for the battered region. In excess of 310,000 homes have been da …
28 October 2020

Nuclear ban: “Today is an historic day. We call on world leaders to act with courage and join the right side of history”
Geneva/New York, 24 October 2020 – The International Red Cross and Red Crescent Movement welcomes the coming into force of the UN Treaty on the Prohibition of Nuclear Weapons (TPNW). Fifty States have now ratified the Treaty, meaning that it will enter …
24 October 2020


IRC International Rescue Committee [to 31 Oct 2020]
Media highlights [Selected]
Press Release
The Trump Administration sets new all-time low number for refugee admissions at 15,000 for fiscal year 2021
October 28, 2020

Press Release
The International Rescue Committee warns against worrying rise of misinformation in crisis-affected states, imperiling fight against COVID-19
October 28, 2020


IVAC [to 31 Oct 2020]
Updates; Events
No new digest content identified.


IVI [to 31 Oct 2020]
Selected IVI News, Announcements, Events
International Vaccine Institute honored with Minister of Health and Welfare Award for achievements in biosafety
October 28, 2020, SEOUL, Korea —  The International Vaccine Institute (IVI) received an award by the Minister of Health and Welfare of the Republic of Korea for achievements in biosafety management…


JEE Alliance [to 31 Oct 2020]
Selected News and Events
No new digest content identified.


MSF/Médecins Sans Frontières [to 31 Oct 2020]
Latest [Selected Announcements]
Coronavirus COVID-19 pandemic
MSF responds as COVID-19 arrives in Jordan’s largest refugee camp
Project Update 28 Oct 2020

Prevention is better than cure – vaccinating against measles in Timbuktu
Project Update 27 Oct 2020
… Despite the official end of the war in 2015, Timbuktu region in northern Mali remains tense, and security incidents and criminality have had a significant impact on people’s ability to access healthcare. This in turn has led to low rates of vaccination coverage, especially among children.
Since February, a number of measles cases have been reported in the area and in September Médecins Sans Frontières (MSF), alongside the Ministry of Health, decided to launch a vaccination campaign. The campaign reached over 50,000 children aged between six months and 14 years…

Negligent and dangerous COVID-19 response in Vathy camp, Samos
Project Update 26 Oct 2020
Médecins Sans Frontières (MSF) is urging the Greek authorities to immediately scale up their response to COVID-19 in Vathy camp on Samos island and transfer people at high risk to safe accommodation on Greece’s mainland or in other EU states.
Vathy camp, which hosts 4,300 people, has registered more than 100 positive cases of COVID-19, yet the authorities have so far failed to put an appropriate medical response in place. Forty asylum seekers in the camp are at risk of developing severe symptoms and at least 10 people have serious medical conditions that cannot be addressed at Samos hospital. Only one army doctor and three nurses are available at the camp…


National Vaccine Program Office – U.S. HHS [to 31 Oct 2020]
No new digest content identified.


NIH [to 31 Oct 2020]
Selected News Releases
NIH scientists discover key pathway in lysosomes that coronaviruses use to exit cells
October 28, 2020 — Targeting cells’ ‘trash compactor’ could lead to new antiviral strategy to fight COVID-19.

Scientists use clues in the human genome to discover new inflammatory syndrome
October 27, 2020 — Study used a “search the genome” approach to reveal how mutations in a gene called UBA1 are associated with inflammatory diseases.


PATH [to 31 Oct 2020]
Press Release
South American countries meet to discuss rollout of new innovations for malaria elimination
October 30, 2020
Experts and policymakers met to review research and plan for the pilot introduction of a new treatment protocol for P. vivax malaria in the Americas, against the backdrop of the COVID-19 pandemic.
…“The new tools open a new horizon to eliminate malaria in Brazil, Peru, and Colombia. The feasibility study will be conducted to inform if health services can implement the new treatment scheme. If the results are as expected then we will be able to expand radical cure through these new tools,” said Alejandro Llanos-Cuentas, professor at Universidad Peruana Cayetano Heredia.
Brazil, Colombia, and Peru have embraced PAHO’s malaria elimination goals but face the challenges of advancing malaria control among ​hard-to-reach populations in the Amazon and other territories with limited coverage of services. In light of these challenges, there is a desire to explore new tools that may help to increase treatment effectiveness.
As of October 2020, tafenoquine has been approved by the US Food and Drug Administration; Australia’s Therapeutic Goods Administration; the Thai Food and Drug Administration; and the Brazilian Regulatory agency (ANVISA). The SD Biosensor STANDARD™ G6PD Test has already been approved in Brazil…

Press Release
PATH and Wondfo partner to develop a point-of-care rapid diagnostic test for G6PD deficiency
Point-of-care diagnostics for G6PD deficiency, a common hereditary condition, play a critical role in supporting the appropriate treatment of Plasmodium vivax malaria


Sabin Vaccine Institute [to 31 Oct 2020]
Statements and Press Releases
Skoll Foundation Funds Sabin Vaccine Institute, Dalberg and JSI Research & Training Institute, Inc. to Establish COVID-19 Vaccine Equity Project
October 28, 2020
As COVID-19 vaccine developers generate clinical evidence of safety and effectiveness needed for vaccine approval, this project will help prepare for the efficient and equitable distribution of vaccines globally by ensuring that national immunization programs have the resources and health systems in place to achieve sustainable global protection from COVID-19 by 2022 and strengthen capacity for vaccination across the life span…
The COVID-19 Vaccine Equity Project will comprise three phases designed to rapidly assess vaccine distribution landscape, maximize learnings and scale a successful pilot to enable equitable global delivery of vaccines. The Skoll Foundation is funding Phases 1 and 2. In Phase 1 (“Plan”), the group will collaborate with Sabin’s Boost Community members to coordinate with ACT-A and select the four countries in which to pilot the project. In Phase 2 (“Pilot”), all three partners will work hand-in-hand with national and subnational immunization professionals to analyze the pilot countries’ needs regarding vaccine financing, procurement and distribution; leading to the creation of tailored action plans for equitable delivery of COVID-19 vaccines. As additional funders join the project, these action plans will serve as a blueprint for Phase 3, in which a successful pilot will be scaled to more than 40 countries and expanded beyond COVID-19 vaccines to strengthen life-course immunization; an approach that prioritizes timely and effective vaccination throughout the lifespan…


UNAIDS [to 31 Oct 2020]
Selected Press Releases/Reports/Statements
30 October 2020
UNAIDS saddened by the death of Valentin Pokrovsky, a Russian leader on HIV, medicine and pandemic preparedness

30 October 2020
Bringing HIV and COVID-19 testing services to hard-to-reach areas in Uzbekistan

29 October 2020
Working with allies to keep comprehensive sexuality education alive

27 October 2020
COVID-19’s impact on HIV vertical transmission services reversed

26 October 2020
Key populations have suboptimal knowledge of their HIV status


UNICEF [to 31 Oct 2020]
Selected Press releases, Statements
UNICEF Executive Director Henrietta Fore’s remarks at Indiana University on “Access to Learning for the World’s Children: Reimagining Education for the Post-COVID World”
Checked against delivery

Press release
Children in the poorest countries have lost nearly four months of schooling since start of pandemic – UNESCO, UNICEF and World Bank report finds
New report looks at national education responses to COVID-19 including lost learning; remote learning support for students, parents and teachers; school reopening plans; health protocols; and financing

UNICEF Executive Director Henrietta Fore’s remarks at the World Health Summit Panel “Accelerating the SDG-3 Global Action Plan for Health and Wellbeing”
As prepared for delivery

Press release
Malnutrition surges among young children in Yemen as conditions worsen
One in five children under the age of five in parts of Yemen are estimated to be acutely malnourished and in urgent need of treatment as malnutrition cases increase across the south, UN agencies warn


Unitaid [to 31 Oct 2020]
Featured News
27 October 2020
Delivering innovation for children
A technology landscape by Unitaid and WHO
Children continue to suffer disproportionately from preventable and treatable diseases such as tuberculosis, malaria, HIV and co-morbidities in low- and middle-income countries.
One of the reasons behind this is the lack of availability of child-friendly health products, despite recent progress in tackling these diseases.
The new technology landscape released by Unitaid, in collaboration with WHO, provides an overview of existing and pipeline technologies that could better allow for more effective administration of essential medicines to children.  The report highlights potential opportunities to apply innovation to critical formulations that meet the unique needs of children.
“The landscape shows the untapped potential to innovate and tackle the challenges facing millions of children needing to take medicine and affected by the deadliest infectious diseases,” said Dr Philippe Duneton, Unitaid Executive Director. “Unitaid, WHO and its partners are exploring which innovative delivery systems could enable faster access to better-tailored treatments for children”.

26 October 2020
UnitaidExplore keeps seeking!
26 October 2020
UnitaidExplore is looking to improve child health outcomes by developing better delivery systems for children’s medicines for use in low resource settings. Delivery and formulation solutions of interest may include—but are not limited to! —micro-needles, supportive technologies such as taste-masking, enhancement of bioavailability, and others described in the Unitaid landscape Innovative Delivery Systems for Paediatrics Medicines. UnitaidExplore aims to support transformative solutions and we are open to diverse technologies; surprise us!

Press Release on the appointment of Dr Philippe Duneton as Unitaid’s new Executive Director
26 October 2020
Geneva – The Unitaid Executive Board is delighted to announce the appointment of Dr Philippe Duneton as Executive Director.
Dr Duneton played an essential role in the founding of Unitaid as well as in the numerous successes achieved by the organization since then. He has been acting Executive Director since March 2020 and has been instrumental in leading Unitaid’s response to the COVID-19 pandemic…


Vaccination Acceptance Research Network (VARN) [to 31 Oct 2020]
No new digest content identified.


Vaccine Confidence Project [to 31 Oct 2020]
Research and Reports
No new digest content identified.


Vaccine Education Center – Children’s Hospital of Philadelphia [to 31 Oct 2020]
Vaccine Update for Providers
October 2020
:: December 2020 event Registration is now open for the Dec. 9, 2020, Current Issues in Vaccines webinar. Dr. Offit’s presentation will be an Update on SARS-CoV-2 vaccines
The event will start at noon ET, and free continuing education credits will be offered for the live and archived event (CME, CEU, and CPE).


Wellcome Trust [to 31 Oct 2020]
Opinion | 29 October 2020
A look inside the global partnership that’s working to find and deliver Covid-19 treatments
Paul Schreier, Chief Operating Officer, Wellcome
Finding and delivering Covid-19 treatments worldwide requires global collaboration at an unprecedented scale. Paul Schreier describes how the ACT-Accelerator Therapeutics Partnership works and what it needs to achieve its mission.


The Wistar Institute [to 31 Oct 2020]
Press Releases
Oct. 29, 2020
Wistar Creates a New Synthetic DNA Vaccine Against Powassan Virus
Vaccine protects animals against tick-borne Powassan virus, an emerging infectious disease.


WFPHA: World Federation of Public Health Associations [to 31 Oct 2020]
Latest News
No new digest content identified.


World Organisation for Animal Health (OIE) [to 31 Oct 2020]
Press Releases
OIE and FAO kickstart global initiative to stop spread of deadly pig disease





ARM [Alliance for Regenerative Medicine] [to 31 Oct 2020]
Press Releases
No new digest content identified.


BIO [to 31 Oct 2020]
Press Releases
New Strategic Vision for Biotechnology Innovation Organization
October 27, 2020
The Biotechnology Innovation Organization (BIO) today announced a new, strategic direction that will help guide it to achieving long-term goals while maintaining responsiveness to changing political headwinds…

After at least 106 one-on-one conversations with member companies, extensive strategic planning sessions, a broad membership survey and several focus groups, BIO outlined the new direction through
:: a new mission – to drive a bio revolution through education, collaboration, and advocacy,
:: a new purpose – to cure patients, protect our climate and to nourish humanity; and
:: a new vision – a world of rapid biotech innovation that is equitably harnessed for health, sustainability and justice.

BIO plans to execute on the strategic direction though five different pillars:
[1] Be a voice of science and for science.
[2] Unite and empower biotech innovators and their ecosystem to improve lives.
[3] Remove barriers to innovation.
[4] Champion broad access to biotech breakthroughs and scientific quality.
[5] Catalyze resilient and sustainable bio-based economies.

The Board and staff of the nearly 1000-member organization plan to operationalize the five pillars beginning immediately. For more information on BIO’s new strategic direction, visit


DCVMN – Developing Country Vaccine Manufacturers Network [to 31 Oct 2020]
News; Upcoming events
DCVMN Annual General Meeting (Virtual): Vaccines, a healthy future
3 November 2020 to 5 November 2020


ICBA – International Council of Biotechnology Associations [to 31 Oct 2020]
No new digest content identified.


IFPMA [to 31 Oct 2020]
Selected Press Releases, Statements, Publications
No new digest content identified.


PhRMA [to 31 Oct 2020]
Selected Press Releases, Statements
Press Release
The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development
Tom Wilbur   |     October 28, 2020